Avalo Therapeutics (AVTX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
2 Jun, 2026Opening remarks and agenda
Chairman welcomed participants and introduced the virtual format for the meeting.
CEO called the meeting to order and introduced board members, management, legal counsel, and auditors present.
Agenda and rules of conduct were outlined, with instructions for submitting questions and voting procedures.
Board and executive committee updates
Board members and key executives, including legal and accounting representatives, were introduced.
Shareholder proposals
Three proposals were presented: election of seven directors, approval of an amendment to the Employee Stock Purchase Plan, and ratification of the independent auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Avalo Therapeutics
- Abdakibart achieved robust efficacy and safety in HS, supporting advancement to Phase 3.AVTX
Corporate presentation13 May 2026 - Strong Phase 2 data and $405M equity raise position the lead asset for pivotal Phase 3 trials.AVTX
Q1 202613 May 2026 - Virtual meeting on June 2, 2026, covers director elections, plan amendment, and auditor ratification.AVTX
Proxy filing10 Apr 2026 - Shareholders will vote on board elections, compensation plans, and auditor ratification at the virtual meeting.AVTX
Proxy filing10 Apr 2026 - Abdakibart targets IL-1β in HS, aiming for best-in-class efficacy with phase 2 data due Q2 2026.AVTX
Corporate presentation23 Mar 2026 - 2025 saw higher R&D spending and net loss, with cash runway projected into 2028.AVTX
Q4 202523 Mar 2026 - AVTX-009 targets IL-1β in HS, with phase II-B data expected Q2 2025 and plans for broader use.AVTX
Leerink Global Healthcare Conference 202610 Mar 2026 - AVTX-009 aims for superior efficacy in HS with high affinity, robust trial design, and broad potential.AVTX
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - AVTX-009 targets central HS inflammation, with pivotal phase II data expected next quarter.AVTX
Oppenheimer 36th Annual Healthcare Life Sciences Conference25 Feb 2026